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Advances in microsurgical techniques and immunomodulatory protocols have contributed
to the expansion of vascularized composite allotransplantation (VCA) with very encourag-
ing immunological, functional, and cosmetic results. Rejection remains however a major
hurdle that portends serious threats to recipients. Rejection features in VCA have been
described in a number of studies, and an international consensus on the classification of
rejection was established. Unfortunately, current available diagnostic methods carry many
shortcomings that, in certain cases, pose a great diagnostic challenge to physicians espe-
cially in borderline rejection cases. In this review, we revisit the features of acute skin
rejection in hand and face transplantation at the clinical, cellular, and molecular levels. The
multiple challenges in diagnosing rejection and in defining chronic and antibody-mediated
rejection in VCA are then presented, and we finish by analyzing current research directions
and novel concepts aiming at improving available diagnostic measures.
Keywords: vascularized composite allotransplantation, transplant rejection, Banff classification, reconstructive
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INTRODUCTION
Reconstructive transplantation using vascularized composite tis-
sue was introduced to clinical reality in 1998 with the first hand
transplant (1), and in 2005 with the first face transplant (2). These
were built on many years of basic and preclinical research aiming
largely at establishing the immunobiology of vascularized com-
posite tissue allotransplantation (VCA). This type of transplanta-
tion is unique as it carries complex immunologic challenges. Effec-
tively, VCA consists of various heterogeneous tissue types of dif-
ferent antigenicity, including skin, vasculature, muscle, cartilage,
tendon, nerve, bone, bone marrow (BM), and vascularized BM.
The high immunogenicity of the skin and, to a lesser extent vas-
culature, necessitate the utilization of multi-immunosuppressive
drug regimens (sometimes administered in high doses) in order
to prevent skin rejection and graft failure. Initial experiences
with hand transplantation in 1964, although technically successful,
failed to overcome such immunologic challenges; severe rejection
occurred 2 weeks postoperatively, and required re-amputation (3).
Subsequently investigators were urged to withhold further clinical
trials until more basic science research is conducted.
Today, up to 26 facial and close to 100 hand allotransplan-
tations have been performed worldwide with excellent short-to-
intermediate functional and immunological outcomes. Rejection
however remains a major obstacle to broader application of VCA,
and poses serious threats to recipients. About 85% of all patients
experienced at least one episode of acute skin rejection within
the first postoperative year, and as much as 56% experienced
multiple episodes (4). Rejection features in VCA have been studied
at the clinical, cellular, and molecular levels, and an international
standardized classification system for the diagnosis and grading
of skin rejection was established (5). However, this system carries
multiple inherent weaknesses due its almost exclusive reliance on
non-specific clinicopathologic cues. Furthermore, the cellular and
molecular basis of skin rejection in VCA, although partially delin-
eated, remain largely unknown. Hence the diagnosis of rejection
in VCA is a major challenge. The aim of this review is to present the
scope of this challenge, highlighting the current unmet diagnostic
needs in VCA and analyzing current and future research directions
working towards overcoming such hurdles. We will first revisit the
salient features of acute skin rejection in hand and face transplan-
tation, underlining their close similarities to those described in
various inflammatory dermatoses; second, we will discuss chronic
and antibody-mediated rejection (AMR) in VCA, highlighting the
pitfalls of available studies investigating these emerging topics;
finally, we will analyze the applicability of emerging concepts and
novel topics in transplantation pathology to the field of VCA.
ACUTE SKIN REJECTION IN HAND AND FACE TRANSPLANTS
REVIEW OF CLINICAL, CELLULAR, AND MOLECULAR FINDINGS
In 1980, Dvorak et al.’s initial experimental work on rejection of
vascularized human skin allograft demonstrated that microvas-
cular endothelium is the critical target of the immune response,
and that rejection manifests largely by vascular damage followed
by ischemic infarction (6). They provided further evidence that,
along these vascular changes, both major T-cell subsets, CD4+
(helper/inducer), and CD8+ (cytotoxic/suppressor), infiltrate the
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skin forming perivascular cuffs (7). These eventually penetrate
the epidermis and lead to dyskeratosis of epidermal and adnexal
keratinocytes (6).
This model is partly similar to a VCA with rejection histologi-
cal changes appearing initially in form of perivascular infiltrates in
the dermis; however, major immunologic differences exist. First,
a variety of immunosuppressive and immunomodulatory proto-
cols are used in VCA (8) which impacts the dynamics rejection;
second, the skin, being transplanted with other components in a
VCA, is rendered less antigenic (9) which might alter the timing
and intensity of rejection episodes.
In this regard, a comprehensive understanding of the basic
cellular and molecular dynamics of rejection in VCA is crucial
for demystifying rejection mechanisms and ultimately devising
accurate and specific diagnostic measures.
Hand transplantation
In hand transplantation, acute rejection manifests by changes
either in the skin or less often in the palm and nail beds.
“Typical” picture.
Macroscopic features. Macroscopic features of skin rejection
include a maculopapular erythematous rash of diverse color inten-
sities. It may be diffuse, patchy or focal, and with or without
burning pain (10–12). It is distributed over the dorsal and volar
aspects of the forearm and wrist, and the dorsum of the hand. This
represents the “classical” pattern of rejection, sparing palmar skin
and nails.
Microscopic features. As for the microscopic features, these are
summarized by the Banff classification of hematoxylin-/eosin-
stained sections (5): Grade I includes mainly lymphocytic perivas-
cular aggregates in the dermis. In mild rejection stages, the
inflammatory infiltrate is found in the interstitium and inter-
phase between dermis and epidermis and/or adnexal structures.
Moderate rejection is characterized by cellular infiltrate in the
epidermis. Advanced stages are characterized by necrosis of ker-
atinocytes resulting in focal dermal-epidermal separation, and
finally necrosis with loss of the epidermis.
Immunohistochemical features. Immunohistochemically, the
infiltrate in acute skin rejection is comprised predominantly of
CD3+ T-cells spreading with progression of rejection from the
perivascular space to the dermis and epidermis. Among CD3+
cells, a tendency toward a predominance of CD8+ T-cells in
milder cases and CD4+ T-cells in advanced cases is observed.
Furthermore, depending on the grade of rejection, 10–50% stain
positive for CD68, a total of 0.5–5% for CD20 and CD79a, and
about 5–10% for FoxP3 (13). As for Indoleamine 2,3-dioxygenase
(IDO) positive cells, these are mostly found scattered in the der-
mis in grade I rejection (14). The involvement of Foxp3 and
IDO in promoting tolerance in VCA remains speculative although
some studies suggested a synergistic role of both molecules in
the setting of CTLA4 Ig induced tolerance in murine cardiac
allografts (15).
“Atypical” picture. An “atypical” pattern of hand rejection has
been described involving palmar skin and nail beds. This occurred
in patients exposed to repetitive and persistent mechanical stress
of the palm (16).
Macroscopic features. Macroscopic features consist of fingers
swelling and a desquamative rash associated with dry skin, red
papules, scaling, and lichenification of the palm. Burning pain
was reported in a minority of patients. Nail involvement is
characterized by dystrophy, degeneration, deformation, or even
loss. Worth noting that there were some erythematous lesions
affecting the forearm and/or the dorsum of the hand (typi-
cal picture features). These however resolved spontaneously, or
responded to conventional treatment, whereas those on the palm
did not (17).
Microscopic features. On the microscopic level, biopsies of pal-
mar skin showed variable degree of lymphocytic infiltrate. That
commenced in the perivascular and perineural areas of the dermis
(grade 1), and progressed into the superficial dermis with erosion
of basal epidermis in some cases. There was also epidermal“hyper-
keratinization,” with evidence of spongiosis and cytoid bodies. As
for the nail bed, biopsy showed a lymphocytic infiltrate, similar to
what was observed in the palmar skin (17).
Immunohistochemical features. Immunohistochemistry revealed
a prevalence of T-cells (CD3+), together with a small number of
B-cells (CD20+ and CD79a). The T-cell infiltrate predominantly
comprised CD4+ T-cells and, to a lesser extent, CD8+ T-cells.
There was a minority of CD68+ macrophages and FoxP3+ cells,
and no C4d staining.
Face transplantation
In face transplantation, the high antigenicity of the oral/nasal
mucosa compounds the immunologic challenge imparted by the
skin. In a minority of cases, a sentinel skin graft (SSG) from the
donor was transplanted for surveillance biopsies and monitoring
of clinicopathologic signs of graft rejection (2, 18).
Macroscopic features. These include skin redness, swelling, and
appearance of nodules and papules (19, 20). The oral mucosa
is erythematous, and a SSG, when present, will display diffuse
edema and erythema. In this situation, since the appearance of
the facial graft (red macules) is different than that of the SSG
(diffuse redness), it is important to differentiate rejection from
various facial dermatoses manifesting with erythema (seborrheic
dermatitis, rosacea, psoriasis, contact dermatitis, etc. . .). A Peri-
odic acid-Schiff stain of the oral mucosa is recommended not to
miss a fungal infection (21).
Microscopic features. Microscopically, pathologic changes seen
in skin and mucosal biopsies during rejection are qualitatively
similar to those observed in hand rejection. The dermis shows
edema and a predominantly lymphocytic inflammatory infiltrate
of variable density; in the surface epithelium (epidermis or mucous
membrane), intercellular edema, lymphocyte exocytosis, basal cell
vacuolization, and keratinocyte apoptosis are noted (13). The
severity of these changes can be assessed according to the same
scoring system proposed for hand transplantation (22). Interest-
ingly, biopsies of the oral mucosa show more severe changes than
Frontiers in Immunology | Alloimmunity and Transplantation November 2013 | Volume 4 | Article 406 | 2
Sarhane et al. Rejection in vascularized composite allotransplantation
those seen on the SSG and the facial graft (23, 24). The explanation
for this observation is unclear; it could be due to a higher density
of antigen-presenting cells (dendritic and Langerhans cells) in the
mucosa as opposed to skin.
Immunohistochemical features. Immunohistochemical studies
showed that T-cells infiltrating the facial graft, oral mucosa, and
SSG expressed predominantly a CD4+ phenotype, with fewer cells
expressing CD8+. Most biopsies contained within the perivascular
dermal infiltrate a small percentage (about 10%) of cells express-
ing cytotoxic associated TIA-1 antigen. FoxP3+ T-regulatory cells
(T-regs) were found in small amounts (10–15% of the infiltrate)
in most mucocutaneous biopsies, mainly within the dermis but
occasionally in the surface epithelium whenever significant exocy-
tosis was present. An admixture of occasional CD20+ B-cells was
found in some biopsies too (13).
ANALYSIS OF CLINICAL FINDINGS
Interestingly, from a clinicopathological view, changes seen dur-
ing facial allograft rejection were similar to those observed during
rejection of other skin-containing composite allografts, such as
hand (25, 26) and also abdominal wall (27), suggesting that rejec-
tion manifests microscopically in the skin in a rather similar way.
Similarly, with respect to cellular dynamics, these were also compa-
rable in hand and face transplantation, consisting predominantly
of CD3+/CD4+ T-cells, with a lower percentage of CD8+ or
TIA-1+ cytotoxic T-cells (28).
Immune mechanisms of acute skin rejection
Understanding the immune mechanisms of acute skin rejection
aids in making an early diagnosis and delivering appropriate
treatment. Knowledge of these mechanisms is also critical in devel-
oping strategies to treat/reverse rejection and in devising new
immunomodulatory therapeutic strategies to ensure longer sur-
vival of these transplants. We will provide below a brief overview
of this topic as this is not the main focus of our review.
It is well known that the complex machinery of transplant rejec-
tion is orchestrated by T-cell adaptive alloimmune responses (29).
The typical acute rejection usually occurs a few days after trans-
plantation, the time necessary for the activation, proliferation, and
differentiation of T-cells. This immune response is dependent on
three signals: alloantigen recognition, activation of T-cells, and
signal for T-cell proliferation (30). Alloantigen recognition (the
first signal) can occur by three different mechanisms: (a) Direct
pathway: alloreactive T-cells directly recognize intact allogeneic
MHC molecules expressed on donor cells (namely APCs) (31).
(b) Indirect pathway: alloreactive T-cells recognize processed allo-
geneic MHC molecules expressed on recipient APCs (32). (c)
Indirect pathway: alloantigens are transferred from donor APCs
to recipient APCs, through cell–cell contact or through transfer
of donor exosomes (33). It is presumed that the direct pathway
is the major cause underlying rejection occurring early on post-
transplantation; its contribution to late rejection is minimal. The
indirect pathway is the main player in later rejection. The role of
the semi-direct pathway in triggering rejection episodes at specific
time points post-transplantation remains to be determined.
Emerging research on mechanisms of transplant rejection is
taking a different approach by focusing on the contribution of
the innate myeloid cells to the development of transplant immu-
nity. There is now evidence that the innate immune system of the
recipient modulates adaptive immune responses through activa-
tion of a number of cells, ligands, receptors, transcription factors,
chemokines, and cytokines (34). Other factors, namely ischemia-
reperfusion injury (35) and complement system activation (36),
come into play and modulate the rejection alloimmune reaction.
With regard to the cellular and molecular players inducing skin
rejection specifically, a neutrophil-mediated stimulation and pro-
gression of acute rejection, described previously in murine cardiac
grafts (37), has been suggested as one of the relevant mechanisms
in VCA. Also, endothelial IDO and adhesion molecules on the
endothelium of graft vasculature (ICAM-1, E-selectin, and LFA-
1) were shown to be associated with the presence and severity of
rejection. The inhibition of E- and P-selectin by Efomycine M in a
rat hindlimb transplantation model, and the subsequent allograft
acceptance underlines their role in promoting skin rejection (14).
Non-specificity of acute skin rejection features
Pathological changes of skin rejection in VCA evolve accord-
ing to the severity of rejection; although characteristic, they are
non-specific and closely resemble several inflammatory dematoses
(21). Effectively, grade I rejection presenting clinically with minor
erythema, and pathologically with mild perivascular infiltrates
resembles manifestations of mild viral infections. The picture
gets further complicated in grade II rejection as the differential
diagnosis of grade II features is much broader. The moderate ery-
thematous changes sometimes seen with scaling, and associated
with denser perivascular infiltrates (with or without epidermal
exocytosis/spongiosis) can also occur in viral infections, dermato-
phyte infection, drug allergic reactions, contact dermatitis, as well
as insect bites. As for grade III consisting of lichenoid plaques or
papules (in the form of hyperkeratosis, hypergranulosis, or acan-
thosis) and associated with even denser dermal infiltrates affecting
the epidermal appendages and reaching the lower epidermal lay-
ers mimics the clinical picture of cutaneous pseudolymphomas,
or even full blown B-cell lymphomas, and various other der-
matoses characterized by lichenoid appearance (lichen planus,
lichenoid drug eruptions, erythema multiforme, lupus erythe-
matosus). Grade IV rejection, documented so far in the first
human hand transplant only, and consisting of necrotizing events
with epidermal necrosis, resembles severe drug reactions (toxic
epidermal necrolysis). It is worth noting that presence or absence
of these manifestations in the recipient’s own skin might be ben-
eficial in guiding the diagnosis. Also a careful review of the past
medical history of the recipient and donor is crucial.
CHRONIC REJECTION IN HAND AND FACE TRANSPLANTS
Despite a high incidence of acute rejection in VCA as compared
to solid organ transplantation, chronic rejection might be a much
rarer event. At present, the exact mechanisms of chronic rejection
have not been defined. It was noted however that both immuno-
logic and non-immunologic factors are implicated (38); but still,
insufficient data are available to describe VCA features of chronic
rejection. The Banff 2007 and 2011 classifications did not include
any characteristics of chronic rejection (5, 39). Clinicopathologic
features suggestive of chronic rejection could include myointimal
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proliferation of arterioles, loss of adnexa, nail changes, skin and
muscular atrophy, and fibrosis of deep tissues (5). Recently, a group
from Lyon (40) has thoroughly assessed four bilateral hand-grafted
patients (10, 7, 3, and 2 years of follow-up, respectively) and one
facial allotransplantation (5 years of follow-up) by histology, mag-
netic resonance imaging, ultrasonography, and high resolution
peripheral quantitative computed tomography scan. There were
no lesions suggestive of chronic rejection, namely dermal fibrosis
or vascular stenosis. Similar results were described by the Inns-
bruck group in their 10 year report update (41). The absence of
chronic rejection in VCA might be due to the fact that all episodes
of acute rejection were diagnosed at an early stage and treated
immediately.
Worth noting that an acute arterial thrombosis due to intimal
hyperplasia in a unilateral hand-grafted recipient was reported
to occur 275 days after transplantation; although the patient had
four episodes of untreated acute rejection, the cause of that
thrombosis was not well defined (42). These untreated acute rejec-
tion episodes might actually be the cause, since in experimental
rat hindlimb models, changes such as intimal hyperprolifera-
tion and luminal narrowing/occlusion consistent with chronic
rejection or allograft vasculopathy were shown to occur after
repeated episodes of acute skin rejection and frequent lapses
in maintenance immunosuppression (43). Of note, this study,
investigating tissue-specific pathological changes secondary to
multiple AR episodes in complete mismatch transplants, does
not accurately reproduce a chronic rejection model; effectively,
the mechanism of rejection is thought to be a continuous sub-
clinical process as opposed to multiple episodes of clinically
overt rejection. Similarly, in another study of chronic rejec-
tion histopathology in a non-human primate model of VCA,
Mundinger et al. were also able to detect transplant vascu-
lopathy features in their model of chronic rejection (44); how-
ever, this model, also relying on complete mismatch transplants
treated with full immunosuppression followed by complete with-
drawal of medications 200 days later, does not accurately repro-
duce the immune reaction responsible for a chronic rejection
phenomenon.
In humans, Kaufman et al. reported some degree of trans-
plant vasculopathy in six of their hand transplant recipients,
with aggressive and severe intimal hyperplasia observed early
post-transplant in two patients (45). True that vascular lesions
such as intimal proliferation and luminal occlusion are reminis-
cent of chronic rejection in solid organ transplantation, however
it is still difficult to affirm that acute ischemia of the grafted
upper extremity in the absence of other previous signs, is a
clinical manifestation of chronic graft rejection in VCA (42).
Clearly, there is an urgent need for appropriate animal models
to study chronic rejection in VCA. In solid organ transplanta-
tion, Fisher to Lewis rat transplantation is regarded as a well-
established and reproducible model for chronic allograft rejection
(46). In such models the histopathological changes observed in
the rejecting renal allograft were comparable to those observed
during chronic rejection in humans (47). Using this model in
VCA might provide a solid platform for analyzing the underly-
ing immune and non-immune mechanisms involved in chronic
rejection pathogenesis.
ANTIBODY-MEDIATED REJECTION IN HAND AND FACE
TRANSPLANTS
While cellular mediated rejection in VCA has been largely stud-
ied, AMR is not well described. In some hand transplant protocol
biopsies, C4d complement deposition was evaluated in an effort to
examine AMR. These were found in approximately 50% of all skin
biopsies, but no correlation with graft function or cellular rejection
could be established (48–50). Additionally, vascular C4d deposits
may be found in inflammatory dermatoses unrelated to rejection
(51). Hence, the reproducibility, sensitivity, and specificity of C4d
as the advocated marker for AMR is limited. This causes a consider-
able number of AMR cases to be C4d negative, and thus not meet-
ing current Banff criteria (39). Other markers of AMR are worth
evaluating, namely IgG, IgM, IgA, C1q, C3d, and especially anti-
HLA class I and class II (also termed donor-specific antibodies,
DSA). DSA were found in some hand transplant recipients, but did
not correlate with C4d deposition in skin biopsies. Recently,a study
using a rat heterotopic hindlimb transplant model showed that
rejection is accelerated but does not occur hyperacutely in the pres-
ence of allosensitization and preformed DSA. This type of rejec-
tion was mainly cell mediated, and differed mechanistically from
that observed in solid organ transplants (52). Although AMR has
been identified as a major cause for allograft failure in renal trans-
plantation (53), the long-term effects of these antibodies in VCA
remain to be elucidated. Presently, little evidence points to a sig-
nificant role of AMR in VCA (54). The lack of knowledge in AMR
aspects represents a major obstacle for conducting clinical tri-
als to develop adapted treatment protocols for sensitized patients
suffering from debilitating limb injuries and severe disfigurement.
This cutting-edge area of transplantation pathology needs suitable
animal models for further investigations of rejection mechanisms.
Valuable lessons are to be learned from the solid organ transplanta-
tion literature (55), and we believe that a rat orthotopic himdlimb
partial mismatch transplant using allosensitized recipients might
be a viable option for studying AMR in VCA.
NOVEL CONCEPTS IN DIAGNOSING REJECTION IN HAND
AND FACE TRANSPLANTS
Although the diagnosis of skin rejection in VCA is guided by an
internationally standardized system (5), inherent shortcomings
related to histophathological reading and interpretations exist.
It is widely recognized that no histological lesion observed in a
skin biopsy from a VCA is absolutely specific for a given diagno-
sis. Furthermore, this method of diagnosis is largely subjective,
in that different clinicians (or even the same physician on differ-
ent days) may report different interpretations of the same biopsy
(56). Not only skin rejection lesions are non-specific and mimic
several inflammatory, infectious, and some neoplastic dermatoses
(as discussed above) (21), intra- and interobserver reproducibil-
ity, particularly at the interface between borderline rejection and
acute rejection exist (57), and these pose a great diagnostic chal-
lenge. The lack of a reliable approach for diagnosing and grading
skin rejection in VCA represents a significant unmet clinical need.
Objective diagnostic methods such as biological markers might be
helpful. In this regard, a considerable amount of ongoing research
is directed at establishing reliable serologic or cellular markers
that could indicate rejection and even correlate with long-term
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graft outcomes (much as in kidney or liver transplantation). Effec-
tively, over the last decade numerous studies have applied omics
technologies to transplant biopsies or body fluids obtained from
transplant recipients with the aim of discovering more precise
diagnostic, predictive, and even prognostic biomarkers (58, 59).
Other directions are engaged in devising novel strategies centered
on cross-disciplinary approaches combining medicine, immunol-
ogy, mathematics, and computer science. These aim at demysti-
fying the biological processes of rejection in an effort to establish
predictive algorithms for the different grades of rejection based
on cytokines expression levels (60). In these novel approaches,
different sample types might be used for analysis. Ideally, it is best
to use starting material that is as close to the site of rejection as
possible. This may include graft tissue, fluid that might be poten-
tially collected close to the site of rejection, serum/plasma, or even
urine. It is worth mentioning that the concentration of rejection
biomarkers (sampled from the graft) will decrease as one moves
further away; thus it is highest in the graft tissue, lower in inter-
stitial fluid, less in serum/plasma, and might be undetectable in
urine. Noteworthy, that this situation might be reversed in cases of
advanced rejection where graft cellular apoptosis results in pour-
ing of cells’ contents in the blood increasing their concentration
peripherally. Therefore, careful standardization of sampling con-
ditions, i.e., timing but also sampling site (graft [volar vs. palmar,
distal vs. proxiam], serum, urine) is of utmost importance for
obtaining reproducible results (61). When the ultimate goal is
identifying rejection markers that are readily translatable to clini-
cal trials, analyzing blood samples (plasma/serum) is most useful.
In fact, serum is typically preserved in all clinical laboratories, and
all the infrastructure to separate it and analyze it is present in most
academic institutions.
However, all these new diagnostic methods might face great
challenges on their way to clinical use. In fact, since there is no
diagnostic gold standard against which the obtained results can
be validated, any candidate set of biological molecules (whether
DNA, RNA, cytokines, or other proteins) will require indepen-
dent validation in larger prospective studies with different samples
(but using the same platform for initial discovery). Therefore, the
integration of new diagnostic tests and platforms into existing
consensus classifications will need close collaboration between
clinicians, pathologists, molecular biologists, biostatisticians, and
omics specialists. It is through this interdisciplinary collabora-
tion that diagnostic precision will be continuously increased in
transplantation pathology.
CONCLUSION
Vascularized Composite Allotransplantation has emerged over the
past decade as a novel reconstructive and restorative option for
patients with severe tissue defects and disfigurement. Despite
initial incertitude, outcomes exceeded all expectations at the
immunologic, functional, and cosmetic levels. Rejection remains
however a serious threat. Innovative strategies aiming at a bet-
ter understanding of the dynamics and immunology of rejection
in VCA are needed. The real advances will come from studying
the molecular and cellular mechanisms that underlie and precede
rejection, the impact of these mechanisms on long-term graft out-
comes, and the other molecular and cellular changes that impede
the development of donor-specific tolerance. Findings from these
studies are likely to have a broader impact on organ transplan-
tation in general. We have already seen a flow of interest in
multi-disciplinary approaches for devising accurate and repro-
ducible diagnostic strategies for rejection in VCA. Although the
ultimate goal of these studies is to improve the diagnosis of rejec-
tion and even build predictive models, it will be equally important
to develop appropriate animal models in which to test different
aspects of rejection at various times post-transplantation. These
animal models need to recapitulate similar changes and chal-
lenges seen in VCA rejection. To this end, no objective measure
of rejection exist; diagnosis remains largely dependent on clini-
copathologic cues which are overall non-specific. Novel concepts
and technologies for improving this aspect of VCA are ongoing
and hold great promise in advancing the development and wide-
spread application of a safer VCA, favoring the risk-benefit for
such life-changing transplants.
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